Evidence map›Paper›PMID 21142402›Full record

ArticleAIDS research and human retroviruses2011

Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques.

Jeffy George, Egidio Brocca Cofano, Elizabeth Lybarger, Mark Louder, Bernard A P Lafont, John R Mascola, Marjorie Robert-Guroff, Joseph J Mattapallil

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. FoxP3Frontiers in immunology · 2022
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jeffy GeorgeUniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Egidio Brocca Cofano
Elizabeth Lybarger
Mark Louder
Bernard A P Lafont
John R Mascola
Marjorie Robert-Guroff
Joseph J Mattapallil
Uniformed Services University of the Health Sciences · USNational Institutes of Health · US

Funding

Development of a Vaccine for HIVAIDS: Cellular ImmunityZIABC011062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$12.8M
AIDS Animal Models: Cellular Immunology and ImmunogeneticsZIAAI001026 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LAFONT, BERNARD · 2009 to 2012
$2.4M
Mucosal immunity and rectal challengeR01DE019397 · NIDCR · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI MATTAPALLIL, JOSEPH JOHN · 2009 to 2011
$2.4M
Non-human Primate Immunogenicity Studies of HIV-1 immunogensZIAAI005011 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2013
$1.5M
Mucosal Epithelium and Long-Term Anti-Retroviral TherapyR21DE018339 · NIDCR · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI MATTAPALLIL, JOSEPH JOHN · 2007 to 2008
$673k
CD4 T cells and anti-viral control in SIV infectionK22AI071812 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI MATTAPALLIL, JOSEPH JOHN · 2007 to 2008
$270k
Intramural NIH HHSNIAID NIH HHS AI07812NIAID NIH HHS K22 AI071812NIDCR NIH HHS DE018339NIDCR NIH HHS DE019397NIDCR NIH HHS R01 DE019397NIDCR NIH HHS R21 DE018339
6 · The paper itself

Abstract

Regulatory T cells contain a mix of CD4 and CD8 T cell subsets that can suppress immune activation and at the same time suppress immune responses, thereby contributing to disease progression. Recent studies have shown that an increased prevalence of CD8(+)FoxP3(+) T regulatory cells was associated with immune suppression and diminished viral control in simian immunodeficiency virus (SIV)-infected rhesus macaques. Preventing an increase in the prevalence of CD8 T regulatory subsets is likely to lead to a better long-term outcome. Here we show that short-term antiretroviral therapy initiated within 1 week after SIV infection was associated with lower viral set point and immune activation after withdrawal of therapy as compared to untreated animals. Early short-term treated controller animals were found to have better SIV-specific immune responses and a significantly lower prevalence of immunosuppressive CD8(+)FoxP3(+) T cells. Lower levels of CD8(+)FoxP3(+) T cells coincided with preservation of CD4(+)FoxP3(+) T cells at homeostatic levels, and significantly correlated with lower immune activation, suggesting a role for viral infection-driven immune activation in the expansion of CD8(+)FoxP3(+) T cells. Interestingly, initiation of continuous therapy later in infection did not reduce the increased prevalence of CD8(+)FoxP3(+) T cells to homeostatic levels. Taken together, our results suggest that early antiretroviral therapy preserves the integrity of the immune system leading to a lower viral set point in controller animals, and prevents alterations in the homeostatic balance between CD4(+) and CD8(+) T regulatory cells that could aid in better long-term outcome.

Indexed as

Immune ToleranceAnimalsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD8 AntigensForkhead Transcription FactorsMacaca mulattaSimian Acquired Immunodeficiency SyndromeT-Lymphocytes, RegulatoryAnti-HIV AgentsCD8 AntigensForkhead Transcription Factors

Identifiers

PMID21142402
PMCPMC3123528
OpenAlexW2014536097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.